Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Diabetic Kidney Disease

World News: . []

IRVING Texas June 04 2018 GLOBE NEWSWIRE -- Reata Pharmaceuticals Inc NasdaqRETA a clinical-stage biopharmaceutical company, today announced that its licensee Kyowa Hakko Kirin Co Ltd Kyowa Hakko Kirin has initiated a Phase 3 cli nical s...

More news and information about Reata Pharmaceuticals, Inc.

Published By:

Globe Newswire: 12:30 GMT Monday 4th June 2018

Published: .

Search for other references to "reata" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us